Results of analysis of >16,000 U.S. lumbar fusions indicate that LifeNet Health’s ViviGen® Cellular Bone Matrix was associated with significantly lower hospital costs compared to recombinant human bone morphogenetic protein-2 (rhBMP-2).
Specifically, the study showed that average charges associated with procedures using ViviGen were up to $50,000 lower than procedures using rhBMP-2.
Two patient groups (~6,600 treated with ViviGen and 9,600 with rhBMP-2) showed similar rates of subsequent lumbar surgeries and hospital re-admissions during follow-up, despite patients in the ViviGen group having significantly higher rates of comorbidities such as diabetes and cancer prior to initial surgery.
“The data in this robust study continues to highlight the powerful clinical outcomes clinicians and patients are seeing with ViviGen,” said Daniel Osborne, Vice President of Global Marketing and Commercial Strategy at LifeNet Health. “These results emphasize the true economic advantages it offers as well, bringing together successful outcomes and drastically lower costs.”
ViviGen is reportedly the first cellular allograft to focus on recovering and protecting viable, lineage-committed bone cells to support the bone-healing process.
Results of analysis of >16,000 U.S. lumbar fusions indicate that LifeNet Health's ViviGen® Cellular Bone Matrix was associated with significantly lower hospital costs compared to recombinant human bone morphogenetic protein-2 (rhBMP-2).
Specifically, the study showed that average charges associated with procedures using ViviGen were up...
Results of analysis of >16,000 U.S. lumbar fusions indicate that LifeNet Health’s ViviGen® Cellular Bone Matrix was associated with significantly lower hospital costs compared to recombinant human bone morphogenetic protein-2 (rhBMP-2).
Specifically, the study showed that average charges associated with procedures using ViviGen were up to $50,000 lower than procedures using rhBMP-2.
Two patient groups (~6,600 treated with ViviGen and 9,600 with rhBMP-2) showed similar rates of subsequent lumbar surgeries and hospital re-admissions during follow-up, despite patients in the ViviGen group having significantly higher rates of comorbidities such as diabetes and cancer prior to initial surgery.
“The data in this robust study continues to highlight the powerful clinical outcomes clinicians and patients are seeing with ViviGen,” said Daniel Osborne, Vice President of Global Marketing and Commercial Strategy at LifeNet Health. “These results emphasize the true economic advantages it offers as well, bringing together successful outcomes and drastically lower costs.”
ViviGen is reportedly the first cellular allograft to focus on recovering and protecting viable, lineage-committed bone cells to support the bone-healing process.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
